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Abstract
Epigenetic deregulation is considered a common hallmark of cancer. Nevertheless, recent publications have demonstrated
its association with a large array of human diseases. Here, we explore the DNA methylation dynamics in blood samples
during hematopoietic cell transplant and how they are affected by pathophysiological events during transplant evolution.
We analyzed global DNA methylation in a cohort of 47 patients with allogenic transplant up to 12 months post-transplant.
Recipients stably maintained the donor’s global methylation levels after transplant. Nonetheless, global methylation is
affected by chimerism status. Methylation analysis of promoters revealed that methylation in more than 200 genes is altered
1 month post-transplant when compared with non-pathological methylation levels in the donor. This number decreased by
6 months post-transplant. Finally, we analyzed methylation in IFN-c, FASL, IL-10, and PRF1 and found association with the
severity of the acute graft-versus-host disease. Our results provide strong evidence that methylation changes in blood are
linked to underlying physiological events and demonstrate that DNA methylation analysis is a viable strategy for the study
of transplantation and for development of biomarkers.
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Introduction
DNA methylation is an epigenetic regulatory mechanism
essential for cellular differentiation processes and maintenance of
cell type-specific gene expression patterns [1,2,3,4]. Thus, each
cell type possesses a stable and characteristic DNA methylation
landscape that defines them. Nevertheless, environmental and
physiopathological pressures can provoke DNA methylation
changes [5,6,7]. DNA hypermethylation in the promoter region
of tumor suppressor genes is a common hallmark of cancer and its
causal relationship with tumor progression has been clearly
established [8,9]. More recently, alterations in DNA methylation
have been observed in numerous diseases such as Lupus [10],
Alzheimer’s disease [11], diabetes [12,13] and rheumatoid arthritis
[14]. Modifications in DNA methylation also occur in response to
environmental factors such as diet [7]. Hence, a large number of
publications have revealed the fundamental link between epige-
netic deregulation and human disease and consequently, DNA
methylation is gaining increasing importance as a source of
biomarkers and promising therapeutic targets [15].
Despite the clinical relevance of epigenetic alterations in human
disease, the epigenetic approach to the study of solid organ and
bone marrow transplantation has been largely overlooked [16].
DNA methylation plays a critical role during hematopoietic
differentiation and allows the generation of cell diversity in the
immune system [17]. Moreover, it is essential for the establishment
of the specific T helper cells subpopulations [18,19], regulates the
expression of cytolityc genes such as perforins and granzymes in
NK and activated T cells [20], and contributes to the functionality
of memory T cells [21,22]. Taken as a whole, DNA methylation
dynamics in blood are essential for the development of the
immune function and this implies that immunological aspects of
organ transplantation are partially linked to epigenetic regulation.
Obviously, this is especially relevant in the case of bone marrow
and hematopoietic cell transplantation since the donor’s immune
system is transferred to the recipient and thus, immunotherapy
with epigenetic drugs, such as hypomethylating agents, has been
recently studied in hematopoietic cell transplant [23,24].
In this study, we sought to explore how global epigenetic
dynamics in blood are affected after transplantation of hemato-
poietic cells and whether or not DNA methylation patterns change
in response to pathophysiological events. For this purpose, we
examined global DNA methylation levels and promoter specific
methylation in a cohort of 47 patients before and after allogenic
hematopoietic cell transplant (HCT). The results indicated that
changes in DNA methylation occurred not only during the normal
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evolution of the transplanted cells, but also in response to
pathology. These findings exposed the clinical significance of
epigenetic analysis as a diagnostic tool in the field of trans-
plantation.
Results
Analysis of Global DNA Methylation Levels Post-HCT
In order to study whole genome methylation status, we used
pyrosequencing based methylation assay of CpG sites in repetitive
DNA elements. Because of the broad distribution of these
sequences across the genome, their levels of methylation are
considered to be equivalent to the average whole genome
methylation. In this study, we analyzed DNA methylation of the
LINE1 element which is an interspersed repetitive DNA element
that comprises a substantial portion of the genome [25], and the
pericentromeric tandem repeat NBL2 [26] in 47 patients after
hematopoietic cell transplant by pyrosequencing (Table 1). First,
we evaluated the levels of methylation in the donors and in the
recipients before and after the transplant and calculated a differ-
ential of methylation (DMet) that simultaneously compared the
methylation values of all CpG sites analyzed in the amplicon
between two samples (see details in methods section) (Figure 1A).
The DMet mean value for the NBL2 between donors and pre-
HCT recipients (DMet = 12.110) and between pre-HCT recipients
and 1 month post-HCT recipients (DMet = 12.610) were signifi-
cantly higher than between donors and 1 month post-HCT
recipients (DMet = 5.8450) with a p-value lower than 0.001
(Figure 1B). These results indicated that the patients retained the
NBL2 methylation values found in the donor’s blood at 1 month
post-transplant. In addition, long term analysis of NBL2 up to 12
months post-HCT demonstrated that methylation remained
consistently similar to the donor (Figure 1C).
In case of LINE1, methylation levels were very similar in all
samples and no significant differences were observed (Figure 1D).
Therefore, LINE1 analysis did not allow a good discrimination of
the methylation status between donors and recipients 1 month
post-HCT. Nonetheless, LINE1 methylation data from all samples
over time (12 months) showed that the average levels of
methylation remained stable (Figure 1E) and suggested that there
was not a significant epigenetic divergence from the donor and
recipient methylation values during the evolution of the transplant
in the LINE1 element.
Pyrosequencing analysis of LINE1 and NBL2 only provides
limited coverage of the genome so it is possible that other specific
genomic regions where these DNA repeats are underrepresented
or absent do not follow this trend. To further investigate this issue,
we performed a limited methylation study of the subtelomeric
repeat D4Z4 in nine patients 1 month after transplant and
observed that the DMet value between donors and post-HCT
recipients (DMet = 5.620) was significantly lower than between
pre-HCT recipients and post-HCT recipients (DMet = 17.930)
(Wilcoxon signed-rank test, p= 0.003906) (Figure S1). Thus,
subtelomeric methylation levels from the donors are dominant
over the recipient’s levels when blood samples are analyzed after
transplantation, similar to NBL2 methylation analysis.
It is not clear which parameters are affecting NBL2, LINE1 or
D4Z4 methylation. It has been observed previously that age,
gender and race/ethnicity may affect DNA methylation in
repetitive elements [27,28]. Hence, we performed a limited study
with blood samples from a healthy population (n = 90). We could
not observe a clear correlation of NBL2 and LINE1 methylation
with age (Pearson correlation coefficient, p.0.05) or gender
(Wilcoxon, p.0.05) (data not show), although when an arbitrary
cutoff point was set at 20 years, older individual showed higher
levels of methylation in NBL2 and lower in LINE1 (Table S1). In
any case, there was not a linear correlation between DNA
methylation in DNA repeats and aging and thus, the moderate
effect due to aging does not appear to be sufficient to explain the
large inter-individual variability observed in NBL2 methylation.
In summary, these results showed that the recipients stably
retained the global methylation status of the donors after
transplantation.
Changes in Global Methylation Levels are Associated to
HCT Outcomes
Because donor’s NBL2 methylation levels apparently remained
stable in the host after transplantation, we wanted to analyze
whether these values were affected by the transplant outcome. To
this end, we focused on two clinical parameters, mixed chimerism
and acute GVHD, during the first month post-transplant.
The control group comprised patients with complete chimerism
that did not develop GVHD symptoms during the follow up of the
transplant (n = 9). The DMet mean value between donors and the
recipients 1 month after transplant was higher for patients with
mixed chimerism (n = 8, DMet = 9.167) than in the control group
with complete chimerism (n = 9, DMet = 3.400) (Wilcoxon signed-
rank test, p= 0.0014) (Figure 2A). This result was expected because
patients with mixed chimerism had cells from both the donor and
the recipient whereas patients with complete chimerism had lost
the recipient’s cells. In fact, the inherent sensitivity of NBL2
methylation is notably high, with an area under the ROC (AUC)
of 0.911 (Figure 2B). On the other hand, the mean DMet value
between donors and post-HCT recipients was higher in patients
with severe aGVHD (n = 18, DMet = 5.870) than in the control
group (n = 9, DMet = 3.400) or in patients with moderate GVHD
symptoms (n = 10, DMet = 3.341) (Figure 2C) although it showed
a poor discriminative ability (AUC = 0.678) and lacked statistical
significance (Wilcoxon signed-rank test, p= 0.065) (Fig. 2D).
Analysis of Promoter Specific DNA Methylation Post-HCT
Since global DNA methylation patterns in post-transplant
patients were equivalent to donor values and those values also
appeared to change in response to pathophysiological events, we
wanted to evaluate DNA methylation in gene promoters. For this
purpose, we performed microarray-based DNA methylation
profiling in blood samples from a recipient without acute or
chronic GVHD (case 1) and from another recipient with grade III
aGVHD that evolved into chronic GVHD (case 2). In this
analysis, DNA methylation in each probe was considered to be
altered when the value differed more than 20% compared to
donor. Using this criterion, we found 227 CpG sites (216 genes)
with altered methylation values in the case 1 and 238 CpG sites
(226 genes) in the case 2 (Figure 3) (Data Set S1), with only 3 genes
in common between both samples (DEGS1, TRAF1 and
FLJ20273). These differences were also reflected in the gene
ontology analysis on the altered genes, showing a differential
distribution of biological processes between case 1 and case 2
samples, with a preferential enrichment of GO terms related to
immune activation in case 2 (Table S2). On the other hand, 6
months post-HCT, the methylation profile between donor and
post-transplant recipient was notably similar, with only 74 altered
CpG sites (72 genes) in the case 1 (Figure 3) and 37 (37 genes) in
the case 2 (Figure 3) (Data Set S1). These results suggested that
methylation profiles in blood samples tend to normalize during the
evolution of the transplant.
To further explore DNA methylation in gene promoters we
selected four genes whose function has been previously associated
DNA Methylation after Hematopoietic Transplant
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with the immune response to HCT (IFN-c, FASL, IL-10, and
PRF1) [29,30,31] and analyzed their methylation status in a cohort
of 47 patients up to 12 months post-HCT. Because DNA
methylation in gene promoters is usually associated to gene
expression we used in this analysis the real percentage of
methylation instead of the DMet value. Before transplant, we
did not observed differences between donors and recipients in
IFN-c, FASL and IL-10, and only methylation at PRF1 promoter
was significantly different (p = 0.0001) (Figure S2). Nonetheless, we
observed a large divergence from the donor values starting at 1
month post-HCT and, in case of IL-10 and PRF1, methylation
tended to normalize during the evolution of the transplant
Figure 1. Analysis of global DNA methylation levels post-HCT. (A) Diagram of the experimental design. The differences of the global
methylation levels between donors, pre-HCT recipients and post-HCT recipients were assessed by a pyrosequencing based methylation assay of
repetitive DNA elements (LINE1 and NBL2) in whole blood. (B) NBL2 DMet values between donors, pre-HCT recipients, and 1 month post-HCT
recipients. (C) NBL2 DMet mean values between donors and recipients up to 12 months post-transplant. The dotted line marks the DMet mean value
between donors and 1 month post-HCT recipients (DMet= 5.8450). During the follow up of the transplant, the mean values barely deviated from the
initial post-HCT DMet. (D) LINE1 DMet values between donors, pre-HCT recipients and 1 month post-HCT recipients. (E) LINE1 DMet mean values
between donors and recipients up to 12 months post-transplant. The dotted line marked the DMet mean value between donors and 1 month post-
HCT recipients (DMet = 5.383).
doi:10.1371/journal.pone.0056931.g001
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(Figure 4). Although the average methylation values did not greatly
differ overtime, we observed large differences between patients,
particularly during the first few months post-HCT, that could be
mirroring relevant clinical parameters. We focused in aGVHD 1
month post-HCT because is strongly associated to immune
response and typically appears early after transplant. One month
post-HCT, methylation levels of IFN-c and FASL were statistically
lower among patients with severe aGVHD (Wilcoxon signed-rank
test, p,0.05) but were not significant different between the control
group and the recipients with moderate aGVHD symptoms
(Figure 4A and 4B). The discriminative ability in the case of severe
aGVHD is relatively high, with AUC values of 0.782 for IFN-c
and 0.769 for FASL (Figure 4A and 4B). In contrast, IL-10
methylation was higher in patients with aGVHD (Wilcoxon
signed-rank test, p= 0.0203) with an AUC value of 0.764, but it
was not able to discriminate between patients with moderate and
severe aGVHD (Wilcoxon signed-rank test, p= 0.1541)
(Figure 4C). On the other hand, PRF1 methylation values were
not significant different between groups 1 month post-HCT
(Figure 4D). Finally, the correlation between percentage of
methylation and the cellular composition in whole blood was
analyzed in a small number of samples for which flow cytometry
data was available one month post-HCT (n = 17). Although the
sample size was small, we observed statistically significant
correlation between the lymphoid fractions and the DNA
methylation in some of the analyzed genes (Table S3). These
results indicate that DNA methylation is at least partially
dependent of the cellular composition in whole blood.
Discussion
In this study, our aims were to develop a comprehensive
epigenetic approach to study hematopoietic cell transplantation.
We tackled two parallel parameters: 1) global methylation levels by
using pyrosequencing based analysis at repetitive DNA elements of
LINE1, NBL2, and D4Z4; and 2) promoter DNA methylation
profiling by bead array technology and pyrosequencing at specific
gene promoters.
Changes in NBL2, LINE1 and D4Z4 methylation have been
reported in cancer [26,32,33]. Nonetheless, these global methyl-
ation levels can also change in response to environmental factors
such as diet, tobacco smoke, or inflammation, and during the
natural aging process [7]. Thus, the initial question that we wanted
to address is whether or not the interaction between donor cells
and the recipient was able to induce global DNA methylation
changes in the grafted cells. First, the pericentromeric tandem
repeat NBL2 and the subtelomeric element D4Z4 retained the
methylation levels of the donor after HCT and, in case of NBL2,
analysis up to 12 months post-HCT showed that donor’s global
methylation levels remained stable. Therefore, global methylation
levels of NBL2 in blood were not significantly affected by the
interaction between donor and recipient. LINE1 methylation
status was similar between donors and recipients, and importantly,
DMet values did not change over time. These results further
supports the observation that there is not a significant epigenetic
drift after transplant in repetitive DNA elements and thus, the
epigenetic traits acquired by the donor due to environmental
factors or aging are likely to be maintained by the grafted cells in
the recipient.
The second question was whether global methylation can
change in response to physiological events during HCT. Com-
parison of NBL2 methylation between patients with complete and
mixed chimerism showed that patients with mixed chimerism had
a much greater deviation from the donor’s methylation status.
Since NBL2 methylation values post-HCT remained stable, this
result is easily explained by the mixed contribution of donor and
recipient to the blood samples. Global methylation analysis can
accurately segregate patients according to chimerism status and
therefore transplanted individuals also can be considered chimeric,
not only at genetic level, but also at an epigenetic level. Therefore,
Table 1. Patient characteristics.
TOTAL
N = 47
Non-aGVHD
(grade 0)
N = 17
aGVHD
(grade I)
N = 10
aGVHD
(grade II–V)
N = 20 p-value
Age Donors (years) Median 33 26 35 32 0.966
Range (0–63) (4–58) (0–52) (0–62)
Age Recipients (years) Median 30 30 33 21 0.788
Range (1–61) (1–59) (7–56) (6–61)
Disease (%) Malignant 89% (n = 42) 88% (n = 15) 100% (n = 10) 85% (n = 17) 0.646
Other 11% (n = 5) 12% (n = 2) 0% (n = 0) 15% (n = 3)
Donors type (%) Related 66% (n = 31) 76% (n = 13) 80% (n = 8) 50% (n = 10) 0.160
Unrelated 34% (n = 16) 24% (n = 4) 20% (n = 2) 50% (n = 10)
Donor match (%) Matched 95% (n = 45) 100% (n = 17) 100% (n = 10) 90% (n = 18) 0.05
Mismatched 5% (n = 2) 0% (n = 0) 0% (n = 0) 10% (n = 2)
Condition regimen (%) Moderate intensity 25% (n = 12) 35% (n = 6) 40% (n = 4) 10% (n = 2) 0.170
High intensity 75% (n = 35) 65% (n = 11) 60% (n = 6) 90% (n = 18)
Source (%) Peripheral Blood 81% (n = 38) 65% (n = 11) 90% (n = 9) 90% (n = 18) 0.022
Bone Marrow 15% (n = 7) 35% (n = 6) 0% (n = 0) 5% (n = 1)
Umbilical Cord 4% (n = 2) 0% (n = 0) 10% (n = 1) 5% (n = 1)
Chimerism Complete 79% (n = 37) 53% (n = 9) 100% (n = 10) 90% (n = 18) 0.06
Mixed 21% (n = 10) 47% (n = 8) 0% (n = 0) 10% (n = 2)
doi:10.1371/journal.pone.0056931.t001
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intrinsic differences found in the NBL2 methylation values
between individuals can be used to track down the source of the
cells in transplant.
On the other hand, we also observed elevated NBL2 DMet
values in patients with severe aGVHD which could be due to a real
methylation drift as a consequence of the disease. These results
suggested that NBL2 methylation could be used as a surrogate
marker in HCT. Nonetheless, the data did not reach statistical
significance.
In addition to the global DNA methylation analysis during
HCT, we wanted to analyze DNA methylation in gene promoters
which is often associated with modulation of gene expression. We
performed microarray-based DNA methylation profiling in PB
samples from two patients with allogenic cell transplant at two
different times post-HCT. Methylation profiles post-HCT re-
vealed that the methylation signatures in blood at 1 month post-
transplant are markedly altered relative to their donors. Con-
versely, 6 months post-HCT, the methylation signatures were very
similar to the donor suggesting that methylation profiles normalize
overtime. Nonetheless, the difference observed between samples at
1 month post-HCT are unlikely to be due to a methylation drift
post-HCT since this was not observed at global level by
pyrosequencing analysis of repetitive DNA elements. Because we
profiled DNA methylation in whole blood, the difference observed
at promoter levels probably reflect changes in the cellular
composition of the samples and thus normalization of the
methylation profile is mirroring the immune reconstitution in
the recipient. Each hematopoietic cell type possesses a specific
methylation signature [34,35] and consequently the percent
contribution of each cell type to the blood sample results in
changes in the methylation profiles. Therefore, methylation
analysis could be used to detect alterations of the cellular
composition in blood samples if the methylation signature of each
cell type was previously defined and consistent in different
individuals, although additional studies will be needed to validate
this approach.
Additionally, we wanted to explore DNA methylation in gene
promoters during transplant evolution in a larger sample set. For
this purpose, we examined by pyrosequencing genes typically
associated with the immune response to HCT. IFN-c levels are
elevated early during development of GVHD symptoms in both
animal models [36] and patients [37], and therefore it constituted
Figure 2. Changes in NBL2 methylation levels are associated to HCT outcomes. (A) NBL2 DMet between donors and 1 month post-
transplant recipient with complete and mixed chimerism. (B) ROC curve for patients with complete and mixed chimerism (AUC= 0.911). (C) NBL2
DMet between donors and 1 month post-transplant recipients according to severity of aGVHD. (D) ROC curve for patients with severe aGVHD versus
non-aGVHD and moderate aGVHD (AUC= 0.678).
doi:10.1371/journal.pone.0056931.g002
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a good candidate for validation by pyrosequencing analysis. IFN-c
is an immune activating cytokine whose expression is tightly
regulated by DNA methylation. Inverse correlation between DNA
methylation and IFN-c expression has been observed during Th1
differentiation [38] and CD8+ lymphocyte activation [39], and it is
constitutively hypomethylated in NK cells. [40] Consequently, the
hypomethylation at the IFN-c promoter observed in patients with
severe aGVHD suggested enrichment of cytotoxic CD8+, NK, and
Th1 cells in the blood samples in agreement with an expected
expansion of alloreative cells in GVHD. Second, FASL is highly
expressed on activated T cells, plays a major role in T-cell
mediated cytotoxicity, and thus, it constitutes a key element of the
cytolytic response during GVHD in HCT. FASL levels in serum
and mRNA levels in CD4+ and CD8+ T cells are higher among
patients with aGVHD. [30,41] We found that FASL methylation
is notably lower in severe aGVHD which is in agreement with the
role of FASL in GVHD. Reduced FASL methylation suggests an
enrichment of cytolytic cells in the blood samples from these
patients, but further studies are necessary since the methylation
status of FASL in blood cells has not been clearly established.
Thirdly, IL-10 is a cytokine partially regulated by DNA
methylation [42,43] and is mainly expressed by monocytes, Th2
and regulatory T cells which have an inhibitory effect over the
expression of Th1 cytokines. [44] Since IL-10 antagonized Th1
response, it was proposed initially that higher levels of IL-10 may
be associated with lower risk of GVHD. We found higher
methylation levels of IL-10 in blood samples of patients with
aGVHD, suggesting that higher methylation levels yield lower
levels of IL-10 in aGVHD patients. Nonetheless, IL-10 mRNA in
whole blood and protein levels in plasma increased early after
HCT in patients with GVHD. [29,45] This result is only
contradictory with our data if we assume that DNA methylation
in whole blood is directly related to gene expression. Differential
expression profiles in whole blood between two samples could be
caused either by changes in the relative cell composition of the
sample or by changes of the expression profile of a specific cell type
without changes in the relative cellular composition. However,
changes of the methylation profiles are more likely due to changes
of the cellular composition since DNA methylation patterns are
usually stable in terminally differentiated cells. Therefore, it is
possible that DNA methylation in whole blood increase because
cells with hypermethylation at IL-10 promoter are overrepresent-
ed while simultaneously IL-10 levels in plasma increased due to
overexpression in response to stimuli in a specific cell type. Taken
together, if a particular methylation signature in whole blood is
going to be used as a biomarker of disease, it is important to note
that DNA methylation levels do not necessarily mirror mRNA
levels. Finally, perforin (PRF1) is expressed primarily in NK and
CD8+ T cells, and is partially regulated by DNA methylation.
[20,31,46] PRF1 gene is involved in immune mediated cell lysis
Figure 3. Promoter DNA methylation profiling using bead arrays and differential methylation analysis after HCT. Scatter plots
showing DNA methylation in donors versus post-transplant recipients 1 month and 6 months post-HCT. Red dots represent CpG sites with
methylation values altered more than 20% relative to donor values.
doi:10.1371/journal.pone.0056931.g003
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and mRNA levels are elevated in peripheral blood in patients with
aGVHD. [31] We found that PRF1 methylation levels decrease in
almost all samples 1 month post-HCT, although we did not
observe differences between aGVHD and non-aGVHD patients.
In summary, our results demonstrated that DNA methylation
analysis in HCT provides useful information that, with further
studies, it may be useful as a diagnostic tool of relevant clinical
parameters. The development of robust biomarkers for aGVHD
using this strategy will require a much larger discovery set and
validation set; nonetheless, our data support the viability of this
approach as a source of biomarkers in HCT and paves the way for
larger studies. Pyrosequencing-based DNA methylation analysis is
Figure 4. Association of Locus-specific DNA methylation to aGVHD. (A) IFNc methylation up to 12 months post-transplant is shown in the
left panel. The black line marked the mean value in the cohort and the dotted line marked the mean value 1 month post-HCT. In the central panel are
represented IFNc methylation values according to severity of aGVHD 1 month post-HCT. IFNc ROC curve for patients with severe aGVHD versus non-
aGVHD and moderate aGVHD (AUC= 0.782) is shown in the right panel. (B) FASL methylation up to 12 months post-transplant and methylation
values according to severity of aGVHD 1 month post-HCT. FASL ROC curve for patients with severe aGVHD versus non-aGVHD and moderate aGVHD
(AUC=0.769) is shown in the right panel. (C) IL-10 methylation up to 12 months post-transplant and methylation values according to severity of
aGVHD 1 month post-HCT. IL-10 ROC curve for patient with and without aGVHD (AUC=0.764) is shown in the right panel. (D) PRF1 methylation up to
12 months post-transplant and methylation values according to severity of aGVHD 1 month post-HCT.
doi:10.1371/journal.pone.0056931.g004
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relatively inexpensive, is very sensitive, and provides an interesting
alternative to protein and mRNA detection in blood samples,
allowing the development of novel biomarkers in a large array of
human diseases. Further studies will be necessary to fully explore
the potential of DNA methylation analysis in the field of
hematopoietic cell and solid organ transplantation.
Methods
Patients and Samples
DNA samples were obtained from the immunology department
of Hospital Virgen de Arraixa in Murcia (Spain) and the Hospital
Universitario in Salamanca (Spain) according to approved in-
stitutional guidelines. The DNA was obtained from peripheral
blood (PB) samples collected monthly from the time of transplant
up to 1 year when possible. DNA samples from donors and
recipients before transplantation were also obtained. All patients
received allogenic hematopoietic cell transplantation and pro-
phylactic pharmacological treatment for graft versus host disease
(GVHD). The clinical characteristic of the patients are shown in
Table 1. Chimerism was diagnosed by DNA fingerprinting
analysis of microsatellites markers (D5S818, Vwa, D13S317,
D7S820, D8S1179, D21S11, D3S1358, D18S51, FGA and
AMELX/Y) according to institutional guidelines. Diagnosis and
grading of acute GVHD (aGVHD) were established as previously
described [47]. Additionally, DNA samples from healthy individ-
uals (n = 90) were obtained from the Hospital Universitario
Central de Asturias (HUCA). All patients gave their written
informed consent in accordance with the declaration of Helsinki
and the study obtained the approval by the local ethics committee
(Comite´ E´tico de Investigacio´n Clı´nica Regional Del Principado
de Asturias, project number 17/2011).
Methylation Analysis by Pyrosequencing
Sodium bisulfite modification of 200 ng DNA was carried out
with the EZ DNA methylation kit (D5002, Zymo Research, CA,
USA) following the manufacturer’s protocol. Pyrosequencing was
performed by using the PyroMark kit (Qiagen, Germany). Primers
are described in Table S3. The PCR condition was 50 cycles at
95uC for 60 s, 58uC for 30 s, and 72uC for 30 s, followed by 72uC
for 5 min. The biotinylated PCR product was purified, made
single-stranded, and acted as a template in a pyrosequencing
reaction by using the Pyrosequencing Vacuum Prep Tool (Qiagen,
Germany). Methylation levels were quantified by using the
PyroMark Q24 system (Biotage, Sweden). Six CpG sites were
analyzed in NBL2 and D4Z4 sequences and four in LINE1.
Primers for IFN-c, FASL, IL-10 and PRF1 were designed to
analyze one CpG site within the promoter region of each gene.
Primers are described in Table S4.
Differential Methylation Analysis by DMet Method
The differential of methylation (DMet) was developed to allow
accurate evaluation of the global methylation drift between two
samples by using pyrosequencing based methylation analysis in
repetitive DNA elements. TheDMet was calculated as the Euclidian
squared distance in n-space: d(p,q) = ((p12 q1)
2+ (p22 q2)2+…+(pn
2 qn)
2)0.5. By this method, each CpG site within the amplicon was
treated as a spacial dimension and the methylation values in each
CpGsitedefineda coordinate inann-space.Therefore, nequaled the
number of CpG sites in the amplicon. The distance between the
coordinates obtained from two samples was the differential of
methylation (DMet). This method allowed a very precise assessment
of the methylation drift given that it was not affected by non-
informativeCpGsitesorbyoppositemethylationdriftbetweenCpGs
within the same amplicon. In addition, theDMetvalue comprised the
methylation drift between two samples in a single value, facilitating
statistical analysis and data plotting.
Promoter DNA Methylation Profiling using Bead Arrays
and Differential Methylation Analysis
Microarray-based DNA methylation profiling was performed on
blood samples from a patient without acute or chronic GVHD and
those from a patient with grade III aGVHD that evolved into chronic
GVHD. Samples analyzed for each case included donor pre-HCT
and recipient samples at 1 month and 6 months post-HCT. Bisulfite
conversion of DNA was performed using the EZ DNA Methylation
Kit (Zymo Research, CA, USA) according to manufacturer’s
procedures. Processed DNA samples were hybridized to the
HumanMethylation27 DNA Analysis BeadChip (Illumina, San
Diego,CA)andthearrayswerescannedontheIlluminaiScansystem.
Raw data were imported and analyzed with the BeadStudio software
(version 3.1.3.0 Illumina, Inc) and methylation values were obtained
as described [48]. Probes with detection p-values of greater than 0.01
wereexcluded fromtheanalysis. In this study,DNAmethylationafter
HCT in each specific probe was considered to be altered when the
value differed more than 20% relative to the donor value. The raw
microarray data have been submitted to the NCBI Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under de
accession number GSE36832. Gene ontology (GO) analysis was
performed with the DAVID GO Web-based tool [49,50]. Re-
dundant GO terms with identical gene hits were excluded in
Supporting Information Table 2.
Statistical Analysis
Analysis was performed with R.2.10 statistical software (www.r-
project.org). Due to the asymmetry of the variables, the median
was considered the measure of central tendency for statistical
calculations. The Wilcoxon test was used to compare the
difference between variables. The discriminative ability of the
variables was described by receiver operating characteristic (ROC)
curves and summarized by the area under the curve (AUC) values.
P-values lower than 0.05 were considered significant.
Supporting Information
Figure S1 Analysis of D4Z4 DNA methylation levels post-HCT.
D4Z4 DMet values between donors, pre-HCT recipients, and 1
month post-HCT recipients.
(TIF)
Figure S2 Promoter DNA methylation analysis in donors and
recipients before HCT. Methylation values were measured by
pyrosequencing analysis in pre-HCT samples. Significant differ-
ences were assessed by the Wilcoxon signed-rank test.
(TIF)
Table S1 Association between age and global DNA methylation
in blood samples.
(DOC)
Table S2 Gene ontology analysis 1 month post-HCT.
(DOC)
Table S3 Correlation between DNA methylation and lymphoid
levels measured by flow cytometry in blood samples 1 month post-
HCT (n = 17) (*p,0.05, **p,0.01).
(DOC)
Table S4 Primer sets for pyrosequencing and sequences to
analyze.
(DOC)
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Data Set S1 Promoter DNA methylation profiling using bead
arrays and differential methylation analysis after HCT.
(XLS)
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